Yoshimi Endo Greer, M.D., Ph.D.
Dr. Yoshimi E. Greer has extensive experience in cell biology, molecular biology, biochemistry and oncology. Her recent research focuses are 1) TRAIL-induced cell death, and 2) mitochondria in cancer. She is exploring potential clinical applications utilizing those mechanisms in cancer treatment. One of her studies has recently contributed to launch clinical trials in breast and endometrial cancers at NCI. She is always seeking exciting collaborations across the NIH campus to promote science discovery in cancer field.
MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer..Breast Cancer Research. 21(1): 27, 2019. [ Journal Article ]
- Oncotarget. 9: 18454-18479, 2018. [ Journal Article ]
- Science Signaling. 9: 415, 2016. [ Journal Article ]
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl..Breast Cancer Res Treat. 155(2): 235-51, 2016. [ Journal Article ]
- Oncoscience. 2(2): 75-6, 2015. [ Journal Article ]
Dr. Yoshimi E. Greer obtained her M.D. in 1994 from Tohoku University School of Medicine, Japan. She conducted clinical residency training in internal medicine for 5 years. In 1999, she received Ph.D. in renal physiology the Graduate School of Tohoku University, Japan.
In 1998, she joined Dr. Josephine P. Briggs' lab at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as a postdoctoral fellow. In 2001, she transferred to Dr. Jeffrey S. Rubin's lab in NCI, and studied Wnt signaling in cancer. In 2004, she joined Lombardi Comprehensive Cancer Center, Georgetown University Medical School in Washington DC as a research instructor, and studied breast cancer.
In 2006, she returned to NCI as a research fellow, and continued Wnt signaling research in cancer. In 2009, she became a staff scientist in the Laboratory of Cellular and Molecular Biology (LCMB), CCR.
In 2014, she joined Dr. Stan Lipkowitz’s lab to explore her great interest in oncology and translational research in breast cancer. Her current research focuses are 1) to develop breast cancer treatment strategies utilizing TRAIL/Death Receptor, 2) to investigate the role of mitochondria in cancer as a therapeutic target.